Topical Drug Reduces Aging Signs and Speeds Wound Healing in Mice
Similar Articles
New Drugs Target 'Zombie' Cells to Combat Cancer and Aging
Review Maps Paths to Target Senescent Cells for Anti-Aging Interventions
Scientists Reverse Aging in Blood Stem Cells by Repairing Lysosomes
Study Finds Stabilizing Key Protein Reduces Frailty in Aging Mice
Engineered Nanoparticles Show Promise in Restoring Brain Waste Removal in Alzheimer's Mouse Model
A topical drug called ABT-263, designed to clear aged cells, improved skin health and wound healing in older mice. After a five-day treatment, 80% of treated mice had fully healed wounds by day 24, compared to 56% of untreated mice. The research, published in the journal Aging, suggests a potential new approach for treating age-related skin decline.
Facts First
- Topical ABT-263 reduced signs of cellular aging in the skin of aged mice.
- Treated mice healed wounds faster, with 80% fully healed by day 24 versus 56% of untreated mice.
- The drug is a senolytic designed to selectively remove senescent cells that accumulate with age.
- Treatment increased gene activity linked to collagen, blood vessel growth, and tissue remodeling.
- The effect was specific to aged mice and was not observed in young mice.
What Happened
Researchers from Boston University applied a topical senolytic drug, ABT-263, to the skin of aged mice for five days. The treatment reduced signs of cellular aging and led to faster wound healing. By day 24 of the study, 80% of the treated mice had fully healed wounds, compared to 56% of the untreated mice. The treatment boosted gene activity related to collagen production, blood vessel growth, and tissue remodeling.
Why this Matters to You
This research points toward a future where age-related skin decline and slow healing could be treated more directly. If similar effects translate to humans, it could lead to new topical treatments that help older skin repair itself more effectively after injury or surgery. This may reduce recovery times and improve outcomes for chronic wounds, which are a significant health concern for the aging population.
What's Next
The findings build on other recent studies, including a 2026 study that used a wound dressing carrying ABT-263 to improve diabetic wound healing in mice. Further research is needed to confirm the safety and efficacy of topical senolytics in humans. Scientists will likely explore whether this approach can be combined with other treatments to enhance skin health and repair as part of the broader field of targeting cellular senescence to combat aging.